Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

After getting beat up on all sides from market observers who don’t much care for the latest mega-deal to arrive in biopharma, at least one prominent analyst now is starting to like what he sees in the numbers for AbbVie/Allergan.